


The burden of antimicrobial resistance (AMR) in Slovenia

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **200 lives** have been lost each year since 1990 in Slovenia due to AMR.
- In 2021, there were an estimated **173 UI (146-201)** deaths attributable to AMR and **821 UI (694-948)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Escherichia coli* resistant to fluoroquinolones and *Pseudomonas aeruginosa* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Slovenia, a 10% reduction means to decrease the number of deaths associated with AMR to **788**, but currently the trend for this country could reach up to **936 UI [744-1,130]** AMR-associated deaths in 2030.

AMR in Slovenia

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Slovenia between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Slovenia** in 2021, there were an estimated **173 UI (146-201)** deaths attributable to AMR and **821 UI (694-948)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Slovenia has the 13th lowest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden rank	Overall susceptible and resistant		Associated		Attributable	
	Bacteria	Annualized rate of change (1990-2021)	Bacteria	Annualized rate of change (1990-2021)	Bacteria	Annualized rate of change (1990-2021)
	Staphylococcus aureus 542 UI (468-615)	↑	Escherichia coli 204 UI (170-239)	↑	Staphylococcus aureus 40 UI (29-50)	↓
	Escherichia coli 324 UI (280-369)	↑	Staphylococcus aureus 155 UI (130-180)	↓	Escherichia coli 37 UI (28-45)	↑
	Streptococcus pneumoniae 195 UI (169-221)	↓	Pseudomonas aeruginosa 72 UI (58-85)	↓	Acinetobacter baumannii 22 UI (19-26)	↓
	Pseudomonas aeruginosa 173 UI (149-197)	↓	Streptococcus pneumoniae 71 UI (55-86)	↓	Pseudomonas aeruginosa 18 UI (14-23)	↓
	Klebsiella pneumoniae 129 UI (111-146)	↓	Klebsiella pneumoniae 68 UI (53-84)	↓	Klebsiella pneumoniae 16 UI (12-20)	↓
	Enterococcus faecalis 78 UI (67-89)	↑	Acinetobacter baumannii 60 UI (51-70)	↓	Streptococcus pneumoniae 10 UI (8-13)	↓
	Acinetobacter baumannii 70 UI (60-80)	↓	Enterococcus faecium 55 UI (46-63)	↑	Enterococcus faecium 7 UI (5-10)	↑
	Enterobacter spp. 60 UI (51-68)	↓	Enterococcus faecalis 32 UI (27-37)	↓	Enterobacter spp. 6 UI (5-7)	↓
	Group A Streptococcus 60 UI (50-69)	↑	Proteus spp. 27 UI (19-36)	↑	Enterococcus faecalis 5 UI (4-7)	↓
	Enterococcus faecium 57 UI (49-66)	↑	Enterobacter spp. 22 UI (17-27)	↓	Proteus spp. 4 UI (2-5)	↑

Annualized rate of change (1990-2021):
 <-3% (dark blue), -1.5% to 0% (light blue), 1.5% to 3% (medium blue), >5.0% (dark red)
 -3% to -1.5% (medium blue), 0% to 1.5% (light blue), 3% to 5% (dark red)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden Rank	Associated		Attributable	
	Combination	Annualized rate of change (1990-2021)	Combination	Annualized rate of change (1990-2021)
	Escherichia coli Aminopenicillin	171 UI (131-211) ↑	Staphylococcus aureus Methicillin	25 UI (15-36) ↑
	Escherichia coli Fluoroquinolones	117 UI (90-145) ↑	Escherichia coli Fluoroquinolones	9 UI (5-14) ↑
	Staphylococcus aureus Methicillin	101 UI (63-140) ↑	Pseudomonas aeruginosa Carbapenems	8 UI (5-12) ↓
	Escherichia coli Beta-Lactam/Lactamase Inhib.	97 UI (78-116) ↑	Escherichia coli Beta-Lactam/Lactamase Inhib.	7 UI (2-13) ↓
	Escherichia coli TMP-SMX	86 UI (57-114) ↓	Escherichia coli Aminopenicillin	7 UI (4-10) ↑
	Staphylococcus aureus Fluoroquinolones	80 UI (61-99) ↓	Acinetobacter baumannii Carbapenems	6 UI (4-9) ↓
	Staphylococcus aureus Macrolides	70 UI (48-93) ↓	Enterococcus faecium Fluoroquinolones	6 UI (3-9) ↑
	Klebsiella pneumoniae Aminoglycosides	60 UI (46-74) ↓	Acinetobacter baumannii Fluoroquinolones	6 UI (5-7) ↓
	Acinetobacter baumannii Beta-Lactam/Lactamase Inhib.	54 UI (44-63) ↓	Staphylococcus aureus Fluoroquinolones	6 UI (2-10) ↓
	Enterococcus faecium Fluoroquinolones	52 UI (44-59) ↑	Klebsiella pneumoniae Aminoglycosides	6 UI (4-7) ↓

Annualized rate of change (1990-2021):
 <-3% (dark blue), -1.5% to 0% (light blue), 1.5% to 3% (medium blue), >5.0% (dark red)
 -3% to -1.5% (medium blue), 0% to 1.5% (light blue), 3% to 5% (dark red)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) bloodstream infections (979 UI (848-1,110)), lower respiratory infection (excl. COVID) (774 UI (662-886)), peritoneal and intra-abdominal infections (398 UI (340-456)), urinary tract infections and pyelonephritis (142 UI (113-171)) and infections of the skin and subcutaneous systems (105 UI (86-123)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Slovenia, people aged 70+ saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that 70+ continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the 70+ was 609 UI (510-707), whereas the mortality rate per 100,000 was 203 UI (170-235).

Data sources for Slovenia

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Slovenia by source type

Source type	Years	Sample size	Sample size units
Microbial or laboratory data without outcome	1990-2021	432,725	Isolates
Microbial or laboratory data with outcome	1990-2021	16,908	Isolates
Literature studies	1990-2009	244	Cases/isolates/susceptibility tests
Single drug resistance profile data	2010-2021	41,286	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>